ILCN.org (ILCN/WCLC) ILCN.org (ILCN/WCLC)
twitter youtube facebook linkedin iaslc Home
  • Home
  • Featured Topics
    • Diagnostic Oncology
      • Early Detection & Screening
      • Evolving Standards of Care
      • Global Initiatives
    • Meeting News
      • Names & News
      • Nursing & Allied Health
      • Patient Advocacy
    • Radiation Oncology
      • Regulatory News
      • Risk Assessment and Reduction
      • Society News
    • Supportive & Palliative Care
      • Surgical Oncology
      • Tobacco & Smoking Cessation
      • WCLC News
  • WCLC News
  • About Us
Menu
  • Home
  • Featured Topics
    • Diagnostic Oncology
      • Early Detection & Screening
      • Evolving Standards of Care
      • Global Initiatives
    • Meeting News
      • Names & News
      • Nursing & Allied Health
      • Patient Advocacy
    • Radiation Oncology
      • Regulatory News
      • Risk Assessment and Reduction
      • Society News
    • Supportive & Palliative Care
      • Surgical Oncology
      • Tobacco & Smoking Cessation
      • WCLC News
  • WCLC News
  • About Us
loading...
Home pembrolizumab

Oncology Trials Could Benefit From Increased Data on Tobacco Use

on: June 23, 2020In: Uncategorized
Oncology Trials Could Benefit From Increased Data on Tobacco Use

By Leah Lawrence Posted: June 24, 2020 As part of its declaration on tobacco cessation after cancer diagnosis, the IASLC recommended that smoking status, both initially and during the study, […] Read more


Single-Agent Pembrolizumab Active Against STK11- and KEAP1- Mutated NSCLC According to KEYNOTE-042 Analysis

on: June 23, 2020In: Meeting News
Single-Agent Pembrolizumab Active Against STK11- and KEAP1- Mutated NSCLC According to KEYNOTE-042
            Analysis

By Kara Nyberg, PhD Posted: June 24, 2020 Genomic alterations in STK11 and KEAP1 represent two of the most common and potent contributors to a cold tumor immune microenvironment in […] Read more

U.S. Drug Approvals: 2010 – 2020

on: April 16, 2020In: Evolving Standards of Care
U.S. Drug Approvals: 2010 - 2020

Posted: April 16, 2020 Read more

Stunning Progress Achieved in Lung Cancer Treatment Over the Last Decade

on: April 15, 2020In: Evolving Standards of Care
Stunning Progress Achieved in Lung Cancer Treatment Over the Last Decade

By Kara Nyberg, PhD Posted: April 16, 2020 After decades of failed clinical trials and persistently dismal lung cancer survival outcomes, the 2010s breathed new life into the beleaguered field […] Read more

PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee

on: April 15, 2020In: Diagnostic Oncology
PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee

By Sylvie Lantuejoul, MD, PhD, and Mari Mino-Kenudson, MD Posted: April 16, 2020 Immune checkpoint inhibitors (ICI), which target the PD-1/PD-L1 axis with the aim of restoring anti-tumor immunity, are […] Read more

Ongoing Immunotherapy Challenges Part II: Defining Benefit for Elderly Patients With NSCLC

on: February 11, 2020In: Systemic, Targeted, & Immune Therapies
Ongoing Immunotherapy Challenges Part II: Defining Benefit for Elderly Patients With NSCLC

This article is the second in a two-part series on ongoing challenges using immunotherapy in special populations. The first part of this series focused on patients with poor performance status.   […] Read more

Journal Radar: Robust Survival Duration Shown in NSCLC With Pembrolizumab

on: December 10, 2019In: Uncategorized
Journal Radar: Robust Survival Duration Shown in NSCLC With Pembrolizumab

By Suresh Ramalingam, MD Posted: December 11, 2019 IN REFERENCE TO: Garon EB, Hellmann MD, Rizvi NA, et al. Five-Year Overall Survival for Patients With Advanced Non–Small-Cell Lung Cancer Treated […] Read more

Concurrent Chemoradiation Followed by Consolidation Therapy: Questions Remain Despite Transformational Data

on: December 10, 2019In: Evolving Standards of Care
Concurrent Chemoradiation Followed by Consolidation Therapy: Questions Remain Despite Transformational
            Data

Posted: November 12, 2019 Now that data from the PACIFIC trial have been incorporated into daily practice, similar trials are validating the results or taking PACIFIC data in new directions. […] Read more

2019 IASLC World Conference on Lung Cancer Updates

on: November 11, 2019In: Meeting News
2019 IASLC World Conference on Lung Cancer Updates

Posted: November 12, 2019 More than 7,700 delegates from around the world attended the IASLC 2019 World Conference on Lung Cancer (WCLC). With sessions and workshops on every aspect of […] Read more

IASLC Logo
ILCN Editorial Group    IASLC.org   

Advertise with Us   

© 2023 IASLC. All Rights Reserved. Powered By TriStar Event Media, LLC   Privacy Policy